Previous 10 | Next 10 |
Nabriva Therapeutics press release (NASDAQ:NBRV): Q1 GAAP EPS of -$0.20 misses by $0.01. Revenue of $8.02M (+218.3% Y/Y) misses by $1.55M. For further details see: Nabriva Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $8.02M misses by $1.55M
-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- -Phase 1 XENLETA Cystic Fibrosis Trial Enrollment Progressing- -Conference Call Today at 4:30 p.m. Eastern Ti...
Ireland's Nabriva Therapeutics (NASDAQ:NBRV) said it extend its exclusive agreement with Merck (MRK) to promote and distribute the Kenilworth, N.J.-based company's antibacterial drug Sivextro in the U.S. till Dec. 31, 2026. Sivextro (tedizolid phosphate) is used to treat patients 12...
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it agr...
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will repo...
DUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that the first patien...
Investment analysts at Northland Securities have lowered their price target on commercial-stage biopharmaceutical company Nabriva Therapeutics (NBRV -9.1%). In a research note published today, the brokerage slashed NBRV's PT from $4.00 to $2.00, while keeping an "Outperform" rating on the sto...
The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2021 Q4 earnings call. For further details see: Nabriva Therapeutics plc 2021 Q4 - Results - Earnings Call Presentation
Nabriva Therapeutics plc (NBRV) Q4 2021 Results Earnings Conference Call March 29, 2022, 04:30 PM ET Company Participants Dan Dolan - Chief Financial Officer Ted Schroeder - Chief Executive Officer Steve Gelone - President and Chief Operating Officer Conference Call Participants Carl Byrnes -...
The commercial-stage pharma company, Nabriva Therapeutics (NASDAQ:NBRV) is trading ~9% lower in the post-market Tuesday after announcing its 4Q 2021 results, which indicated a slowdown in its growth momentum. Revenue for the quarter more than tripled to $9.3M, backed by $8.4M in net...
News, Short Squeeze, Breakout and More Instantly...
Nabriva Therapeutics plc Company Name:
NBRV Stock Symbol:
NASDAQ Market:
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment ...
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Na...
- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, ...